Cancer immunotherapy by immuno-checkpoint blockade

Yutaka Kawakami

研究成果: Article

抄録

As cancer immunotherapies utilizing anti-tumor T-cell responses, immuno-checkpoint blockade and adoptive T-cell immunotherapy have recently achieved durable responses even in advanced cancer patients with metastases. Administration of antibodies on the T-cell surface, CTLA-4 and PD-1 (or PD-1 ligand PD-L1), resulted in tumor regression of not only melanoma and renal cell cancer which were known to be relatively sensitive to immunotherapy, but also various malignancies including lung, bladder, ovarian, gastric, and head and neck cancers, as well as hematological malignancies such as Hodgkin and B-cell malignant lymphomas. These findings have changed the status of immunotherapy in the development of cancer treatments. Currently, development of combinations employing cancer immunotherapy with immuno-checkpoint blockade, as well as personalized cancer immunotherapy based on the evaluation of pretreatment immune status, are in progress.

元の言語English
ページ(範囲)2186-2194
ページ数9
ジャーナル[Rinshō ketsueki] The Japanese journal of clinical hematology
56
発行部数10
DOI
出版物ステータスPublished - 2015 10 1

Fingerprint

Immunotherapy
Neoplasms
T-Lymphocytes
B-Cell Lymphoma
Hematologic Neoplasms
Head and Neck Neoplasms
Hodgkin Disease
Renal Cell Carcinoma
Stomach Neoplasms
Melanoma
Lymphoma
Urinary Bladder
Neoplasm Metastasis
Ligands
Lung
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

これを引用

Cancer immunotherapy by immuno-checkpoint blockade. / Kawakami, Yutaka.

:: [Rinshō ketsueki] The Japanese journal of clinical hematology, 巻 56, 番号 10, 01.10.2015, p. 2186-2194.

研究成果: Article

@article{09064352631b40b094a2560d96ac86dc,
title = "Cancer immunotherapy by immuno-checkpoint blockade",
abstract = "As cancer immunotherapies utilizing anti-tumor T-cell responses, immuno-checkpoint blockade and adoptive T-cell immunotherapy have recently achieved durable responses even in advanced cancer patients with metastases. Administration of antibodies on the T-cell surface, CTLA-4 and PD-1 (or PD-1 ligand PD-L1), resulted in tumor regression of not only melanoma and renal cell cancer which were known to be relatively sensitive to immunotherapy, but also various malignancies including lung, bladder, ovarian, gastric, and head and neck cancers, as well as hematological malignancies such as Hodgkin and B-cell malignant lymphomas. These findings have changed the status of immunotherapy in the development of cancer treatments. Currently, development of combinations employing cancer immunotherapy with immuno-checkpoint blockade, as well as personalized cancer immunotherapy based on the evaluation of pretreatment immune status, are in progress.",
author = "Yutaka Kawakami",
year = "2015",
month = "10",
day = "1",
doi = "10.11406/rinketsu.56.2186",
language = "English",
volume = "56",
pages = "2186--2194",
journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "10",

}

TY - JOUR

T1 - Cancer immunotherapy by immuno-checkpoint blockade

AU - Kawakami, Yutaka

PY - 2015/10/1

Y1 - 2015/10/1

N2 - As cancer immunotherapies utilizing anti-tumor T-cell responses, immuno-checkpoint blockade and adoptive T-cell immunotherapy have recently achieved durable responses even in advanced cancer patients with metastases. Administration of antibodies on the T-cell surface, CTLA-4 and PD-1 (or PD-1 ligand PD-L1), resulted in tumor regression of not only melanoma and renal cell cancer which were known to be relatively sensitive to immunotherapy, but also various malignancies including lung, bladder, ovarian, gastric, and head and neck cancers, as well as hematological malignancies such as Hodgkin and B-cell malignant lymphomas. These findings have changed the status of immunotherapy in the development of cancer treatments. Currently, development of combinations employing cancer immunotherapy with immuno-checkpoint blockade, as well as personalized cancer immunotherapy based on the evaluation of pretreatment immune status, are in progress.

AB - As cancer immunotherapies utilizing anti-tumor T-cell responses, immuno-checkpoint blockade and adoptive T-cell immunotherapy have recently achieved durable responses even in advanced cancer patients with metastases. Administration of antibodies on the T-cell surface, CTLA-4 and PD-1 (or PD-1 ligand PD-L1), resulted in tumor regression of not only melanoma and renal cell cancer which were known to be relatively sensitive to immunotherapy, but also various malignancies including lung, bladder, ovarian, gastric, and head and neck cancers, as well as hematological malignancies such as Hodgkin and B-cell malignant lymphomas. These findings have changed the status of immunotherapy in the development of cancer treatments. Currently, development of combinations employing cancer immunotherapy with immuno-checkpoint blockade, as well as personalized cancer immunotherapy based on the evaluation of pretreatment immune status, are in progress.

UR - http://www.scopus.com/inward/record.url?scp=84965124728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965124728&partnerID=8YFLogxK

U2 - 10.11406/rinketsu.56.2186

DO - 10.11406/rinketsu.56.2186

M3 - Article

C2 - 26458459

AN - SCOPUS:84965124728

VL - 56

SP - 2186

EP - 2194

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 10

ER -